Sign In
Buy CELC
$88.95
-2.47 (-2.70%)
At Close: Jun 03, 2026
Development of a gedatolisib formulation for subcutaneous injection is underway; first patent application submitted to the U.S. Patent and Trademark Office Development of a gedatolisib formulation for
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
08:00am, Thursday, 07'th May 2026
MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will
Why Is Celcuity Stock Rallying Today?
07:05am, Monday, 04'th May 2026
Celcuity Inc. (NASDAQ:CELC) shares are up during Monday's premarket session following positive news about its Phase 3 VIKTORIA-1 trial results.
Detailed data for the gedatolisib triplet and doublet regimens will be presented at a late-breaking abstract oral session at the 2026 ASCO Annual Meeting Detailed data for the gedatolisib triplet and
Celcuity: Best-In-Class Potential With 2-3x Upside If Mutant Data Delivers
10:21am, Wednesday, 29'th Apr 2026
Celcuity (CELC) is rated a cautious Buy, with upside contingent on positive mutant cohort data for gedatolisib in 2L HR+/HER2- advanced breast cancer. Current $6B valuation already prices in significa
Why Celcuity Stock Popped on Monday
06:18pm, Monday, 27'th Apr 2026
An analyst initiated coverage of the biotech.
Nisa Investment Advisors LLC Decreases Stock Holdings in Celcuity, Inc. $CELC
04:58am, Wednesday, 08'th Apr 2026
Nisa Investment Advisors LLC lowered its stake in shares of Celcuity, Inc. (NASDAQ: CELC) by 96.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities
Why Celcuity Stock Popped Today
08:05pm, Thursday, 26'th Mar 2026
It very much surprised on the upside on the bottom-line result. It also has a much longer cash runway than it did at the end of 2024.
Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript
08:15pm, Wednesday, 25'th Mar 2026
Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 25'th Mar 2026
MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
08:00am, Wednesday, 18'th Mar 2026
MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wi
Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of “Moderate Buy” from Analysts
04:28am, Monday, 16'th Mar 2026
Shares of Celcuity, Inc. (NASDAQ: CELC - Get Free Report) have received an average rating of "Moderate Buy" from the ten research firms that are covering the company, Marketbeat Ratings reports. One a
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug
10:28am, Friday, 13'th Mar 2026
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Celcuity Inc. (CELC) Presents at Leerink Global Healthcare Conference 2026 Transcript
04:20pm, Tuesday, 10'th Mar 2026
Celcuity Inc. (CELC) Presents at Leerink Global Healthcare Conference 2026 Transcript
Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing
02:47pm, Tuesday, 10'th Mar 2026
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology and strategic licensing in oncology.
